Form 4: AMERISAFE CFO Converts RSUs, Adjusts Holdings

AMERISAFE's EVP-CFO, Anastasios Omiridis, converted restricted stock units into common stock and sold shares for tax purposes.

Summary

• AMERISAFE's EVP-CFO, Anastasios Omiridis, engaged in transactions involving the company's common stock and derivative securities on August 29, 2025.
• Omiridis converted 4,565 restricted stock units (RSUs) into common stock. These units are part of a larger grant of 22,826 RSUs made on September 1, 2022, with this conversion representing a 20% installment of that grant.
• Concurrently, 1,797 shares of common stock were disposed of at a price of $46.18 per share, likely to cover tax obligations associated with the RSU vesting and conversion.
• Following these reported transactions, Anastasios Omiridis directly holds 5,021 shares of AMERISAFE common stock.
• The reporting person continues to beneficially own 18,922 derivative securities, specifically restricted stock units.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing (Form 4) detailing the vesting and conversion of restricted stock units and a subsequent tax-related sale. It does not inherently indicate positive or negative sentiment about the company's performance or future prospects, but rather reflects standard executive compensation processes.

Positives

• The conversion of restricted stock units into common stock indicates the vesting of executive compensation, aligning management's long-term interests with shareholders.
• Retention of 5,021 shares of common stock post-transaction demonstrates continued direct ownership by a key executive.

Negatives

• A disposition of 1,797 shares of common stock occurred, although this is a common practice for tax withholding upon RSU vesting.

Future Outlook

The remaining restricted stock units from the September 1, 2022 grant are scheduled to vest in future annual installments, specifically the final 30% portion on September 1, 2026. The reporting person holds a total of 18,922 derivative securities (RSUs) following these transactions, indicating future potential conversions into common stock.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies. It reflects standard executive compensation practices involving equity awards like Restricted Stock Units (RSUs) and subsequent tax-related sales upon vesting. Such transactions are closely monitored by investors for insights into management's confidence and ownership stakes.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as part of executive compensation is a common practice in the insurance and broader financial services industry, aligning executive incentives with long-term shareholder value.
• The vesting schedule (e.g., four annual installments) is typical for such equity awards, similar to practices observed at peers like Travelers (TRV) or Chubb (CB) for their executive compensation plans.
• The disposition of shares for tax withholding upon RSU vesting is a standard procedure across industries.

Stakeholder Impact

• Shareholders: Provides transparency into executive ownership and compensation practices. The retention of a significant portion of vested shares by the CFO aligns executive interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Future vesting installments of the remaining restricted stock units from the September 1, 2022 grant will occur according to the original grant schedule (the final 30% portion on September 1, 2026).

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares for tax purposes. Such transactions are standard for executive compensation and do not typically provide new fundamental information that would warrant a change in investment recommendation. The filing itself does not offer insights into the company's operational performance, financial health, or strategic direction that would influence a 'buy' or 'sell' decision. Therefore, a 'hold' recommendation is appropriate as this filing is neutral in its impact on the investment thesis.

Keywords

AMERISAFE, AMSF, Form 4, Insider Trading, Restricted Stock Units, Executive Compensation, Anastasios Omiridis, CFO